Vaxcyte/$PCVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Ticker
$PCVX
Sector
Primary listing
Employees
414
Headquarters
Website
Vaxcyte Metrics
BasicAdvanced
$4B
-
-$4.13
1.21
-
Price and volume
Market cap
$4B
Beta
1.21
52-week high
$116.95
52-week low
$27.66
Average daily volume
1.5M
Financial strength
Current ratio
11.106
Quick ratio
10.755
Long term debt to equity
2.59
Total debt to equity
2.795
Profitability
EBITDA (TTM)
-698.618
Management effectiveness
Return on assets (TTM)
-16.44%
Return on equity (TTM)
-21.65%
Valuation
Price to book
1.31
Price to tangible book (TTM)
1.31
Price to free cash flow (TTM)
-7.291
Free cash flow yield (TTM)
-13.72%
Free cash flow per share (TTM)
-4.252
Growth
Earnings per share change (TTM)
-10.11%
3-year earnings per share growth (CAGR)
17.26%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Bulls say / Bears say
Vaxcyte’s balance sheet remains robust, with cash, cash equivalents and investments of $2.83 billion as of June 30, 2025, underpinning the current operating plan through mid-2028 and funding late-stage PCV development without near-term financing needs (Nasdaq via turn6search3).
The VAX-24 infant Phase 2 dose-finding study delivered positive topline results in March 2025, demonstrating safety and tolerability comparable to Prevnar 20 and robust immunogenicity across all doses, leading to selection of a mid-dose formulation for advancement to a potential Phase 3 program (GlobeNewswire via turn1search0).
Constructive FDA engagement—including input during an End-of-Phase 2 meeting and ongoing Breakthrough Therapy discussions—has streamlined VAX-31’s adult Phase 3 program design, with guidance on CMC and non-inferiority endpoints paving the way for a fourth-quarter 2025 trial initiation and supporting a potential BLA submission upon study completion (GlobeNewswire via turn5search1).
Pipeline narrowing reduces Vaxcyte’s long-term diversification, as the company paused advancement of early-stage candidates VAX-A1 (Group A Strep) and VAX-GI (Shigella) and discontinued VAX-PG (periodontal disease), concentrating resources on PCV programs at the expense of potential revenue streams beyond pneumococcal vaccines (Nasdaq via turn8search0).
Modifications to the VAX-31 infant Phase 2 study—adding an optimized dose arm and removing the low-dose arm—have pushed expected topline safety and immunogenicity data to the first half of 2027, delaying progression to a pediatric Phase 3 program and potential market entry (Nasdaq via turn8search0).
Operating expenses accelerated sharply in Q2 2025, with total GAAP operating costs rising to $226.2 million from $153.0 million a year earlier, driven by a 47.7% increase in R&D and 48.8% in G&A expenses, heightening cash burn and potentially eroding the company’s runway absent further capital raises (Nasdaq via turn8search0).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $4B as of September 16, 2025.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of September 16, 2025.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.